Schrödinger (SDGR) closed at $27.14 on Oct 30, 2026, down 9.5% on the day. The stock is down 10.9% over the past month, up 77.6% over three months, up 51.8% year to date and up 32.6% over the past year (since Oct 30, 2025). It trades 19.7% below its 52-week high of $33.78 and 148.0% above its 52-week low of $10.94. The close sits above its 50-day moving average ($24.96) and above its 200-day moving average ($16.76).
NextPick tracks SDGR in its AI Drug Discovery basket alongside TEM, ABCL, RXRX, ABSI and CERT. As of Oct 30, 2026, the basket's money-flow score is 1 (neutral), and the basket is up 10.2% over five sessions. Over the past month SDGR ranks 5th of 6 basket members by price change.
Form 4 filings over the last 90 days show no open-market purchases and 2 open-market sales by insiders.
Yes — the Oct 30, 2026 close of $27.14 is 62.0% above the 200-day average of $16.76.
SDGR closed 19.7% below its 52-week high of $33.78.
NextPick groups SDGR with TEM, ABCL, RXRX, ABSI and CERT in its AI Drug Discovery basket.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
